Akeso Drug Pipeline

Akeso maintains a substantial clinical portfolio, with 79 active trials out of 139 total registered since 2008. Clinical activity spans from Phase 1 through Phase 3, with 33, 40, and 23 active trials respectively. The portfolio covers five therapeutic areas, but is heavily concentrated in oncology, which accounts for 75% of active programs (59 trials). Within oncology, the leading indications by active trial count are solid tumor (advanced), with 12 active trials, followed by non-small cell lung cancer (NSCLC) with 10 active trials, and hepatocellular carcinoma with 6 active trials. NSCLC, hepatocellular carcinoma, pancreatic cancer, and colorectal cancer each have Phase 3 trials ongoing. Beyond oncology, Akeso has a smaller presence in immunology (4 active trials), respiratory (2 active trials), and central nervous system (1 active trial). The portfolio's strong weighting toward oncology suggests a strategic focus on this therapeutic area.